News and Events

2010

2.22.2010 - Semafore Pharmaceuticals Announces Issuance of Key U.S. Patent Covering Composition of Matter for Novel PI3K/mTOR Pathway Inhibitor

2009

12.8.2009 - Semafore Pharmaceuticals Reports Encouraging Phase I Data at ASH for Novel PI3K/mTOR Pathway Inhibitor; Company also announces plans to expand ongoing Phase I studies into B-cell malignancies

11.16.2009 - Semafore Pharmaceuticals Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st ASH Annual Meeting

09.21.2009 - Semafore Retains Management Consulting Firm; Names Principal to Key Management Position

05.30.2009 - Semafore's SF1126, a vascular targeted pan-PI3K/mTOR inhibitor, is well tolerated and demonstrates acivity in Phase I solid tumor patients; clinical data presented at the 2009 ASCO meeting

03.17.2009 - Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor

2008

12.01.2008 - GEN report: Zeroing in on PI3K Pathway

12.01.2008 - Semafore presents poster "Regulating the Critical PI3 Kinase & PTEN Cell Signals for Major Advances in Targeted Cancer Therapies" at the Cancer-Oncology Summit in Indianapolis, IN

11.14.2008 - Semafore presents "Preclinical and Clinical Experiences with the Targeted PI-3 Kinase Inhibitor SF1126" at the AACR conference "Targeting the PI3-Kinase Pathway in Cancer Research" in Boston, MA

11.13.2008 - Semafore presents poster "SFP6: A New Compound Class of Designed Pan- and Isoform-Selective PI3-Kinase Small Molecule Inhibitors" at the AACR conference "Targeting the PI3-Kinase Pathway in Cancer Research" in Boston, MA